☆ 4.7 Letter

Coding polymorphisms in CD33 and response to gemtuzumab ozogamicin in pediatric patients with AML: a pilot study

LEUKEMIA (2009)

Journal

LEUKEMIA

Volume 23, Issue 2, Pages 402-404

Publisher

NATURE PUBLISHING GROUP

DOI: 10.1038/leu.2008.185

Keywords

-

Categories

Oncology Hematology

Funding

NCI NIH HHS [P30 CA021765-30, CA-21765, P30 CA021765] Funding Source: Medline
NIGMS NIH HHS [U01GM61374, U01 GM061374-07, U01 GM061374, U01 GM61393, U01 GM061393, U01 GM061393-09] Funding Source: Medline

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Oncology

Systematic evaluation of AML-associated antigens identifies anti-U5 SNRNP200 therapeutic antibodies for the treatment of acute myeloid leukemia

Katherine Knorr, Jahan Rahman, Caroline Erickson, Eric Wang, Mara Monetti, Zhuoning Li, Juliana Ortiz-Pacheco, Andrew Jones, Sydney X. Lu, Robert F. Stanley, Maria Baez, Nina Fox, Cynthia Castro, Alessandra E. Marino, Caroline Jiang, Alex Penson, Simon J. Hogg, Xiaoli Mi, Hideaki Nakajima, Hiroyoshi Kunimoto, Koutarou Nishimura, Daichi Inoue, Benjamin Greenbaum, David Knorr, Jeffrey Ravetch, Omar Abdel-Wahab

Summary: Despite recent advances in AML treatment, targeting surface antigens in AML remains challenging due to shared expression across malignant and normal cells. This study identified unique expression of RNA helicase U5 snRNP200 on AML cells but not on normal hematopoietic precursors, as well as skewed Fc receptor distribution in the AML immune microenvironment. Anti-U5 snRNP200 antibodies engaging activating Fc receptors showed efficacy in AML models and were enhanced by combination with azacitidine.

NATURE CANCER (2023)

Add to Collection

Article Health Care Sciences & Services

Cost-effectiveness analysis of gemtuzumab ozogamicin for the treatment of de novo CD33-positive Acute Myeloid Leukaemia (AML) in Italy

Roberto Cairoli, Gianluca Furneri, Roberto Di Virgilio, Barbara Veggia, Felicetto Ferrara

Summary: Based on the ALFA-0701 study, gemtuzumab ozogamicin (GO) in combination with daunorubicin and cytarabine (DA) has been approved as the first line treatment for de novo acute-myeloid leukemia (AML). The cost-effectiveness of GO in combination with DA was assessed compared to DA alone, from the perspective of the Italian National Health Service.

BMC HEALTH SERVICES RESEARCH (2023)

Add to Collection

Review Oncology

CD33 Expression and Gentuzumab Ozogamicin in Acute Myeloid Leukemia: Two Sides of the Same Coin

Matteo Molica, Salvatore Perrone, Carla Mazzone, Pasquale Niscola, Laura Cesini, Elisabetta Abruzzese, Paolo de Fabritiis

Summary: This review focuses on the current biological information and clinical data regarding the use of gemtuzumab ozogamicin (GO) in patients with acute myeloid leukemia (AML). The studies have shown that cytogenetic, molecular, and immunophenotypic data can predict the potential benefits of using GO in AML patients, especially when combined with other approved or experimental drugs. The understanding of molecular mutations and altered intracellular pathways may lead to new therapeutic strategies in AML treatment.

CANCERS (2021)

Add to Collection

Article Oncology

Acute Left Ventricular Dysfunction Following Gemtuzumab Ozogamicin in Two Pediatric AML Patients

Kevin O. McNerney, Katelyn Oranges, Alix E. Seif, Benjamin Oshrine, Bonnie Ky, Kimberly Y. Lin, Kelly D. Getz, Richard Aplenc

Summary: Gemtuzumab ozogamicin (GO) has proven efficacy in treating CD33(+) acute myeloid leukemia but may lead to severe cardiotoxicity. Despite successful recovery of cardiac function with medical therapy and subsequent stem cell transplantation in the two patients, close monitoring of adverse reactions during treatment is still necessary.

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2022)

Add to Collection

Article Hematology

Impact of gemtuzumab ozogamicin consolidation on hematopoietic stem cells (HSCs) mobilization in AML: analysis of 20 patients

Salvatore Perrone, Saveria Capria, Massimo Bernardi, Francesco Marchesi, Elettra Ortu La Barbera, Silvia Maria Trisolini, Clara Minotti, Mahnaz Shafii Bafti, Maria Cristina Scerpa, Antonino Mule, Fabio Ciceri, Maurizio Martelli, Giuseppe Cimino

Summary: Based on the retrospective analysis of patient data, it was found that approximately 55% of patients were able to successfully undergo hematopoietic stem cell transplantation (HSCT) after treatment with GO. However, the use of GO reduced the success rate of HSCT, indicating the need for further research on the impact of fractionated doses of GO on HSCT outcomes.

ANNALS OF HEMATOLOGY (2023)

Add to Collection

Article Oncology

A phase IV study evaluating QT interval, pharmacokinetics, and safety following fractionated dosing of gemtuzumab ozogamicin in patients with relapsed/refractory CD33-positive acute myeloid leukemia

Pau Montesinos, Vamsi Kota, Joseph Brandwein, Pierre Bousset, Rebecca J. Benner, Erik Vandendries, Ying Chen, Mary Frances McMullin

Summary: This study aimed to evaluate the effects of fractionated dosing of gemtuzumab ozogamicin (GO) on the QT interval, pharmacokinetics (PK), and immunogenicity in patients with relapsed/refractory acute myeloid leukemia (AML). The results showed that fractionated dosing of GO is not associated with a clinically significant risk of QT interval prolongation in AML patients, and the presence of antidrug antibodies (ADAs) is not related to potential safety issues.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2023)

Add to Collection

Review Biochemistry & Molecular Biology

Targeted Therapeutic Approach Based on Understanding of Aberrant Molecular Pathways Leading to Leukemic Proliferation in Patients with Acute Myeloid Leukemia

Moo-Kon Song, Byeong-Bae Park, Ji-Eun Uhm

Summary: Acute myeloid leukemia (AML) is a heterogeneous hematopoietic neoplasm characterized by genetic abnormalities that have significant prognostic implications. Understanding the molecular abnormalities of the disease may lead to the development of novel targeted therapies.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Multidisciplinary Sciences

Poor outcome of pediatric patients with acute myeloid leukemia harboring high FLT3/ITD allelic ratios

Kun-Yin Qiu, Xiong-Yu Liao, Yong Liu, Ke Huang, Yang Li, Jian-Pei Fang, Dun-Hua Zhou

Summary: This study explores the relationship between FLT3/ITD allelic ratio and prognosis in pediatric AML patients and identifies an optimal threshold value, highlighting the importance of individualized treatment for pediatric AML.

NATURE COMMUNICATIONS (2022)

Add to Collection

Article Oncology

Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design

Haiying Qin, Lila Yang, John A. Chukinas, Nirali Shah, Samiksha Tarun, Marie Pouzolles, Christopher D. Chien, Lisa M. Niswander, Anthony R. Welch, Naomi Taylor, Sarah K. Tasian, Terry J. Fry

Summary: The development of CAR T cell immunotherapy for AML patients is crucial. Through rigorous preclinical evaluation of CD33 CAR T cells, the best lintuzumab-CD28/CD3 zeta CAR construct was selected for clinical translation, showing potent anti-leukemia activity.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Article Hematology

CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy

Semjon Willier, Paula Rothamel, Maximilian Hastreiter, Jonas Wilhelm, Dana Stenger, Franziska Blaeschke, Meino Rohlfs, Theresa Kaeuferle, Irene Schmid, Michael H. Albert, Vera Binder, Marion Subklewe, Christoph Klein, Tobias Feuchtinger

Summary: Emerging immunotherapies like chimeric antigen receptor T cells have shown progress in treating acute lymphoblastic leukemia, but controlling acute myeloid leukemia poses challenges due to differences in clinical and biological characteristics across age groups.

BLOOD (2021)

Add to Collection

Article Hematology

Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy

Raphael Itzykson, Elise Fournier, Celine Berthon, Christoph Rollig, Thorsten Braun, Alice Marceau-Renaut, Cecile Pautas, Olivier Nibourel, Emilie Lemasle, Jean-Baptiste Micol, Lionel Ades, Delphine Lebon, Jean-Valere Malfuson, Lauris Gastaud, Laure Goursaud, Emmanuel Raffoux, Kevin-James Wattebled, Philippe Rousselot, Xavier Thomas, Sylvain Chantepie, Thomas Cluzeau, Hubert Serve, Nicolas Boissel, Christine Terre, Karine Celli-Lebras, Claude Preudhomme, Christian Thiede, Herve Dombret, Claude Gardin, Nicolas Duployez

Summary: This study identified genetic mutations in AML patients that independently predict overall survival, providing a simple and robust prognostic model. By combining cytogenetic risk and mutations in specific genes, patients can be categorized into different prognostic tiers.

BLOOD (2021)

Add to Collection

Article Hematology

Association of race and ethnicity with clinical phenotype,genetics, and survival in pediatric acute myeloid leukemia

Shannon E. Conneely, Casey L. McAtee, Rohit Gupta, Joseph Lubega, Michael E. Scheurer, Rachel E. Rau

Summary: This study observed that Black and Hispanic children with AML have worse outcomes compared to White children, with certain genetic subtypes being more prevalent in these ethnic groups. Racial-ethnic disparities in survival outcomes were prominent and varied across different cytogenetic subclasses, indicating a need for further exploration of socioeconomic and biological determinants of these disparities.

BLOOD ADVANCES (2021)

Add to Collection

Article Hematology

In-depth time-dependent analysis of the benefit of allo-HSCT for elderly patients with CR1 AML: a FILO study

Raynier Devillier, Edouard Forcade, Alice Garnier, Sarah Guenounou, Sylvian Thepot, Gaelle Guillerm, Patrice Ceballos, Yosr Hicheri, Pierre-Yves Dumas, Pierre Peterlin, Mathilde Hunault-Berger, Marie-Christine Bene, Anne Bouvier, Patrice Chevallier, Didier Blaise, Norbert Vey, Arnaud Pigneux, Christian Recher, Anne Huynh

Summary: The study aimed to investigate the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients aged > 60 years with acute myeloid leukemia (AML) in first complete remission (CR1). The results showed that allo-HSCT significantly improved relapse-free survival (RFS) and overall survival (OS) of these patients, indicating that allo-HSCT is the best curative option for fit older patients with AML.

BLOOD ADVANCES (2022)

Add to Collection

Review Pediatrics

Targeted Therapy in Pediatric AML: An Evolving Landscape

LaQuita M. Jones, Katherine Tarlock, Todd Cooper

Summary: The treatment outcomes of pediatric acute myeloid leukemia have improved over the last few decades with the implementation of intensive chemotherapy and comprehensive genomic sequencing. However, despite the risks and side effects, a portion of patients are still unable to be cured. Advancements in genomic and molecular research are being utilized to develop targeted therapies for pediatric AML to improve outcomes.

PEDIATRIC DRUGS (2021)

Add to Collection

Article Oncology

CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells

Yi Liu, Sanmei Wang, Maria-Luisa Schubert, Annika Lauk, Hao Yao, Maximilian Felix Blank, Chunhong Cui, Maike Janssen, Christina Schmidt, Stefanie Goellner, Christian Kleist, Fengbiao Zhou, Jens-Ulrich Rahfeld, Tim Sauer, Michael Schmitt, Carsten Mueller-Tidow

Summary: Immunotherapies, such as CAR T cells and ADCs, have greatly improved cancer treatment, especially in lymphoid malignancies. The lack of a tumor-specific target antigen has limited the application of targeted immunotherapy in AML patients. A third-generation CAR T-cell product targeting CD33 showed significant anti-leukemia activity in AML and potential for genome-edited stem cell transplantation approaches.

INTERNATIONAL JOURNAL OF CANCER (2022)

Add to Collection

Article Oncology

Vaccines against SARS-CoV-2 are safe to administer in patients with antibodies to pegaspargase

Hope D. Swanson, Hana Hakim, Diego R. Hijano, Ted Morton, Shane Cross, Hiroto Inaba, Sima Jeha, Ching-Hon Pui, Seth E. Karol

Summary: This study aimed to evaluate the safety of SARS-CoV-2 vaccines in patients with anti-pegaspargase antibodies. The results showed that these patients tolerated the vaccines well, which also use polyethylene glycol as a stabilizing agent, with no significant adverse reactions observed.

CANCER MEDICINE (2023)

Add to Collection

Article Oncology

Outcomes of Childhood Noninfant Acute Lymphoblastic Leukemia With 11q23/KMT2A Rearrangements in a Modern Therapy Era: A Retrospective International Study

Andishe Attarbaschi, Anja Moericke, Christine J. Harrison, Georg Mann, Andre Baruchel, Barbara De Moerloose, Valentino Conter, Meenakshi Devidas, Sarah Elitzur, Gabriele Escherich, Stephen P. Hunger, Keizo Horibe, Atsushi Manabe, Mignon L. Loh, Rob Pieters, Kjeld Schmiegelow, Lewis B. Silverman, Jan Stary, Ajay Vora, Ching-Hon Pui, Martin Schrappe, Martin Zimmermann

Summary: This study aimed to investigate the prognostic factors and efficacy of allogeneic hematopoietic stem-cell transplantation (allo-HSCT) in the first remission of patients with noninfant childhood acute lymphoblastic leukemia (ALL) with 11q23/KMT2A rearrangements. The results showed that the prognosis of patients with noninfant 11q23/KMT2A-rearranged ALL has improved compared to historical data, but allo-HSCT did not improve outcomes. Targeted therapies are needed to reduce relapse and treatment-related mortality rates.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Letter Oncology

Clinical characteristics and outcomes of B-cell precursor ALL with MEF2D rearrangements: a retrospective study by the Ponte di Legno Childhood ALL Working Group

Kentaro Ohki, Ellie R. Butler, Nobutaka Kiyokawa, Shinsuke Hirabayashi, Anke K. Bergmann, Anja Moericke, Judith M. Boer, Helene Cave, Giovanni Cazzaniga, Allen Eng Juh Yeoh, Masashi Sanada, Toshihiko Imamura, Hiroto Inaba, Charles G. Mullighan, Mignon L. Loh, Ulrika Noren-Nystrom, Lee-Yung Shih, Marketa Zaliova, Ching-Hon Pui, Oskar A. Haas, Christine J. Harrison, Anthony V. Moorman, Atsushi Manabe

LEUKEMIA (2023)

Add to Collection

Article Oncology

Association between body mass index at diagnosis and outcomes in Chinese children with newly diagnosed acute lymphoblastic leukemia

Wenting Hu, Yin Ting Cheung, Yanjing Tang, Li Hong, Yuan Zhu, Jing Chen, Zhuo Wang, Min Zhou, Yijin Gao, Jing Chen, Benshang Li, Huiliang Xue, Longjun Gu, Shuhong Shen, Jingyan Tang, Ching-Hon Pui, Hiroto Inaba, Jiaoyang Cai

Summary: Studies on the association between BMI at diagnosis and treatment outcomes in Chinese children with ALL have shown inconsistent results. While weight status was not associated with event-free survival or overall survival, overweight patients were at a higher risk of treatment-related mortality.

CANCER MEDICINE (2023)

Add to Collection

Article Hematology

Genome-wide CRISPR/Cas9 screen identifies etoposide response modulators associated with clinical outcomes in pediatric AML

Nam H. K. Nguyen, Roya Rafiee, Abderrahmane Tagmount, Amin Sobh, Alex Loguinov, Angelica K. de Jesus Sosa, Abdelrahman H. Elsayed, Mohammed Gbadamosi, Nathan Seligson, Christopher R. Cogle, Jeffery Rubnitz, Raul Ribeiro, James Downing, Xueyuan Cao, Stanley B. Pounds, Christopher D. Vulpe, Jatinder K. Lamba

Summary: This study utilized CRISPR/Cas9 technology to identify known genes, such as TOP2A and ABCC1, as well as novel genes including RAD54L2, PRKDC, and ZNF451, which may serve as potential therapeutic targets for overcoming treatment resistance.

BLOOD ADVANCES (2023)

Add to Collection

Article Hematology

Characterisation of children and adolescents with acute lymphoblastic leukaemia who presented without peripheral blood blasts at diagnosis

David Spencer Mangum, Johnathon D. Bishop, Yinmei Zhou, Cheng Cheng, Seth E. Karol, Jeffrey E. Rubnitz, Raul C. Ribeiro, Jun J. Yang, Charles G. Mullighan, Sima Jeha, Ching-Hon Pui, Hiroto Inaba

Summary: Among children with acute lymphoblastic leukaemia, about 14.7% presented without peripheral blood blasts. While absence of blasts did not affect survival outcomes, these patients had distinct genetic and clinical characteristics, with a higher incidence of hyperdiploid B-ALL and lower rates of central nervous system involvement.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Add to Collection

Article Oncology

Clinical impact of minimal residual disease and genetic subtypes on the prognosis of childhood acute lymphoblastic leukemia

Chih-Hsiang Yu, Shiann-Tarng Jou, Ying-Hui Su, Elane Coustan-Smith, Gang Wu, Chao-Neng Cheng, Meng-Yao Lu, Kai-Hsin Lin, Kang-Hsi Wu, Shu-Huey Chen, Fang-Liang Huang, Hsiu-Hao Chang, Jinn-Li Wang, Hsiu-Ju Yen, Meng-Ju Li, Shu-Wei Chou, Wan-Ling Ho, Yen-Lin Liu, Chia-Ching Chang, Ze-Shiang Lin, Chien-Yu Lin, Hsuan-Yu Chen, Yu-Ling Ni, Dong-Tsamn Lin, Shu-Wha Lin, Jun J. Yang, Yen-Hsuan Ni, Ching-Hon Pui, Sung-Liang Yu, Yung-Li Yang

Summary: This study analyzed data from two consecutive protocols to determine the clinical impact of minimal/measurable residual disease (MRD) and tumor genetic subtypes in newly diagnosed pediatric acute lymphoblastic leukemia (ALL) patients. The results showed that MRD-directed therapy improved outcomes for pediatric ALL, especially for standard-risk patients. This study provides important data to inform the design of future clinical trials in Taiwan.

CANCER (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Pharmacotypes across the genomic landscape of pediatric acute lymphoblastic leukemia and impact on treatment response

Shawn H. R. Lee, Wenjian Yang, Yoshihiro Gocho, August John, Lauren Rowland, Brandon Smart, Hannah Williams, Dylan Maxwell, Jeremy Hunt, Wentao Yang, Kristine R. R. Crews, Kathryn G. G. Roberts, Sima Jeha, Cheng Cheng, Seth E. E. Karol, Mary V. V. Relling, Gary L. L. Rosner, Hiroto Inaba, Charles G. G. Mullighan, Ching-Hon Pui, William E. E. Evans, Jun J. J. Yang

Summary: Contemporary chemotherapy for childhood acute lymphoblastic leukemia is personalized based on clinical features, leukemia genomics, and minimal residual disease. However, the pharmacological basis of these prognostic variables is unclear. A study analyzing samples from 805 children with newly diagnosed leukemia identified variations in drug response and determined that certain subtypes were more sensitive to specific agents. The findings suggest opportunities for individualizing therapy and exploring alternative strategies for childhood acute lymphoblastic leukemia.

NATURE MEDICINE (2023)

Add to Collection

Article Oncology

An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia

Audrey Lasry, Bettina Nadorp, Maarten Fornerod, Deedra Nicolet, Huiyun Wu, Christopher J. Walker, Zhengxi Sun, Matthew T. Witkowski, Anastasia N. Tikhonova, Maria Guillamot-Ruano, Geraldine Cayanan, Anna Yeaton, Gabriel Robbins, Esther A. Obeng, Aristotelis Tsirigos, Richard M. Stone, John C. Byrd, Stanley Pounds, William L. Carroll, Tanja A. Gruber, Ann-Kathrin Eisfeld, Iannis Aifantis

Summary: This study provides a comprehensive analysis of the bone marrow immune microenvironment in adult and pediatric AML patients. Unique inflammation signatures were identified in a subset of AML patients, which were associated with poor outcomes. Dysfunctional B-cell subtype, atypical B cells, were found to be enriched in high-inflammation AML patients, along with an increase in CD8(+)GZMK(+) and regulatory T cells, and a reduction in T-cell clonal expansion. An inflammation-associated gene score (iScore) was developed which predicts survival outcomes and refines current risk stratifications in AML patients. The study highlights the importance of considering the inflammatory state in clinical settings.

NATURE CANCER (2023)

Add to Collection

Article Oncology

Clinical characteristics and outcomes of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis managed with different cytoreductive methods

Georgios E. Christakopoulos, Kendra N. Walker, Jesse Smith, Clifford M. Takemoto, Yan Zheng, Ching-Hon Pui, Raul C. Ribeiro, Lei Wang, Stanley B. Pounds, Jeffrey E. Rubnitz, Hiroto Inaba

Summary: This study investigated the clinical management strategies and effects of cytoreduction in pediatric patients with acute myeloid leukemia (AML) and hyperleukocytosis. The results showed that LD-cytarabine treatment was safe and effective in reducing leukocyte counts in children with AML and hyperleukocytosis.

CANCER (2023)

Add to Collection

Article Virology

Upper Respiratory Infection Drives Clinical Signs and Inflammatory Responses Following Heterologous Challenge of SARS-CoV-2 Variants of Concern in K18 Mice

Jacob H. Nichols, Evan P. Williams, Jyothi Parvathareddy, Xueyuan Cao, Ying Kong, Elizabeth Fitzpatrick, Richard J. Webby, Colleen B. Jonsson

Summary: The evolution of SARS-CoV-2 has led to the emergence of variants of concern, such as Alpha and Delta, which show increased immune evasion and transmissibility. In a mouse study, it was found that while neutralizing antibodies provided protection against the original strain, reinfection with Alpha or Delta resulted in self-limited viral infection and inflammatory response in the upper respiratory tract. These findings suggest the importance of understanding breakthrough infections and immune response to different variants.

VIRUSES-BASEL (2023)

Add to Collection

Article Virology

Dissecting Phenotype from Genotype with Clinical Isolates of SARS-CoV-2 First Wave Variants

Mariah K. Taylor, Evan P. Williams, Yi Xue, Piroon Jenjaroenpun, Thidathip Wongsurawat, Amanda P. Smith, Amber M. Smith, Jyothi Parvathareddy, Ying Kong, Peter Vogel, Xueyuan Cao, Walter Reichard, Briana Spruill-Harrell, Amali E. Samarasinghe, Intawat Nookaew, Elizabeth A. Fitzpatrick, Micholas Dean Smith, Michelle Aranha, Jeremy C. Smith, Colleen B. Jonsson

Summary: The closely related clinical isolates of SARS-CoV-2 exhibit phenotypic divergence and induce different immune responses. One variant shows faster viral replication and lower mortality rate, with unique immune responses. Lung histopathology reveals distinct phenotypes among the isolates.

VIRUSES-BASEL (2023)

Add to Collection

Article Clinical Neurology

Perioperative multimodal analgesic injection for patients with adolescent idiopathic scoliosis undergoing posterior spinal fusion surgery

Anthony M. Padgett, Seerat Kapoor, Leslie N. Rhodes, Katie Keen, Xueyuan Cao, Lindsey L. Locke, William C. Warner, Jeffrey R. Sawyer, Benjamin W. Sheffer, David D. Spence, Derek M. Kelly

Summary: This retrospective cohort study compared postoperative opioid consumption in patients undergoing posterior spinal fusion for adolescent idiopathic scoliosis. The study found that patients treated with a perioperative multimodal analgesic injection had significantly lower consumption of PRN morphine equivalents and higher rates of ambulation on postoperative day 1 compared to those treated with patient-controlled analgesia.

SPINE DEFORMITY (2023)

Add to Collection

Article Clinical Neurology

Analysis of AVPR1A, thermal and pressure pain thresholds, and stress in sickle cell disease

Keesha L. Powell-Roach, Yingwei Yao, Xueyuan Cao, Srikar Chamala, Margaret R. Wallace, Yenisel Cruz-Almeida, Robert E. Molokie, Zaijie Jim Wang, Diana J. Wilkie

Summary: This study investigated the association between pain and stress in patients with sickle cell disease (SCD), and found that a specific gene SNP was related to acute pain and stress-related pain. Additionally, there was a correlation between clinical pain and environmental stress, but the gene SNP did not modify this correlation. This finding highlights the importance of further exploring the role of this gene SNP in SCD.

FRONTIERS IN PAIN RESEARCH (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.